Gilead at outperform by RBC

RBC Capital Markets analyst Jason Kantor reiterated Gilead Sciences Inc. at outperform, average risk. The analyst believes Gilead's greatest opportunity for growing its franchise is to increase the number of newly diagnosed HIV infections, based on CDC recommendations for HIV testing to increase the rate of diagnosis. These new public health measures should provide lasting growth for Gilead's HIV franchise. Shares of the Foster City, Calif.-based biopharmaceutical company were up 54 cents, or 0.84%, at $64.78. (Nasdaq: GILD)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.